iPS cells under attack

Effie Apostolou and Konrad Hochedlinger ()
Additional contact information
Effie Apostolou: Effie Apostolou and Konrad Hochedlinger are at the Howard Hughes Medical Institute, Center for Regenerative Medicine and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, and at the Harvard Stem Cell Institute, Harvard University.
Konrad Hochedlinger: Effie Apostolou and Konrad Hochedlinger are at the Howard Hughes Medical Institute, Center for Regenerative Medicine and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, and at the Harvard Stem Cell Institute, Harvard University.

Nature, 2011, vol. 474, issue 7350, 165-166

Abstract: Induced pluripotent stem cells offer promise for patient-specific regenerative therapy. But a study now cautions that, even when immunologically matched, these cells can be rejected after transplantation. See Letter p.212

Date: 2011
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/474165a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:474:y:2011:i:7350:d:10.1038_474165a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/474165a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().